Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Feb 24, 2026 - P1/2 | N=53 | Terminated | Sponsor: National Cancer Institute (NCI) | Phase classification: P2 ➔ P1/2 | Completed ➔ Terminated; Unable to supply investigational agent, Zotiraciclib (TG02).
Phase classification • Trial termination • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Gliosarcoma • Oncology • Sarcoma • Solid Tumor • ATRX • TP53
|